ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.
“IMGN388 was well tolerated at doses at which evidence of anticancer activity was observed”
IMGN388, a TAP compound, is designed to target and kill cells that express its αv integrin target. This antigen is found on a number of types of solid tumors, including lung, breast and prostate cancers. It is also found on vascular cells in the process of forming new blood vessels, a process that needs to occur for any solid tumor to grow.
The poster presentation, entitled "A Phase I Study of IMGN388, an Antibody Drug Conjugate Targeting αv Integrin, in Patients with Solid Tumors," reports findings from the trial's dose-finding phase, which was designed to determine the maximum tolerated dose of the compound when administered once every three weeks. In this phase, IMGN388 was found to be well tolerated at doses up to and including 130 mg/m2 (3.5 mg/kg).
Initial evidence of activity also was reported, with four patients remaining on IMGN388 for 18 weeks or longer before disease progression. All but one of these patients was on IMGN388 longer than their last prior therapy. Two of these patients have received the compound for over 30 weeks and were still benefiting from treatment at the time of data analysis for the presentation.
"IMGN388 was well tolerated at doses at which evidence of anticancer activity was observed," commented James O'Leary, MD, Vice President and Chief Medical Officer. "Based on the tolerability of the compound and its pharmacokinetic profile, our next step will be to evaluate IMGN388 when administered on a more frequent basis."